| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
University Laboratory of Physiology, Oxford OX1 3PT, United Kingdom
 |
ABSTRACT |
|---|
 Top
 Abstract
 Introduction
Methods
Results
Discussion
References
|
|---|
The role of the cardiac muscarinic-receptor-coupled nitric oxide (NO) pathway in the cholinergic control of heart rate (HR) is controversial. We investigated whether adding excessive NO or its intracellular messenger cGMP could significantly modulate the HR response to vagal nerve stimulation (VNS) in the anesthetized rabbit and isolated guinea pig atria. The NO donor molsidomine (0.2 mg/kg iv) significantly enhanced the decrease in HR seen with right VNS (5 Hz, 5 V, 30 s) in vivo. A qualitatively similar effect was seen with the NO donor sodium nitroprusside (SNP; 10 and 100 µM) during VNS in vitro. This effect was still present when the baseline shift in HR caused by SNP was eliminated by using the specific hyperpolarization-activated current antagonist 4-(N-ethyl-N-phenylamino)-1,2-dimethyl-6-(methylamino)-pyrimidinium chloride (ZD-7288, 1 µM). The accentuated decrease in HR with SNP during VNS was mimicked by the stable analog of cyclic GMP, 8-bromoguanosine 3',5'-cyclic monophosphate (0.5 mM). This, however, was not seen with bath application of the stable analog of acetylcholine, carbamylcholine chloride (100 nM). We conclude that excessive NO enhances the magnitude of the decrease in HR caused by VNS. This effect appears to involve a presynaptic action via a cGMP-dependent pathway because it was not mimicked by bath-applied carbamylcholine chloride.
nitric oxide; vagal; heart rate; guanosine 3',5'-cyclic monophosphate
| |
INTRODUCTION |
|---|
|
Top
Abstract
Introduction
Methods
Results
Discussion
References
|
|---|
NITRIC OXIDE (NO) is widely established as a signaling molecule in the cardiovascular system. Many of its modulatory effects are mediated by the intracellular messenger cGMP, which is produced after activation of the enzyme guanylate cyclase by NO. It is synthesized from L-arginine by a family of enzymes known as NO synthases (NOS). Cardiac myocytes and the coronary vasculature express endothelial NOS (1, 15), and neuronal NOS is distributed in peripheral cardiac autonomic nerves (10, 16, 18, 25, 31, 35) and in neurons in autonomic regions of the brain (9, 23, 32). Recently, it has been suggested that NO may play an important role in the parasympathetic control of heart rate (HR) via a M2-receptor-coupled activation of a NO pathway that modulates the ion channels involved in cardiac pacemaking (8).
The precise role of NO in the cholinergic control of HR is still,
however, unclear and indeed controversial. In single sinoatrial node
cells, non-isoform-selective inhibition of NOS abolishes the
cholinergic inhibition of adrenergically stimulated L-type calcium
channel current
(ICa L)
(8), and in endothelial NOS-disrupted murine ventricular myocytes,
there is selective impairment of the muscarinic cholinergic inhibition
of adrenergically stimulated ICa L
(7). However, Vandecasteele et al. (34) found no evidence for a role of the NO-cGMP pathway in the magnitude of the change in
isoprenaline-stimulated calcium current with acetylcholine in isolated
human atrial myocytes. Moreover, Liu et al. (17) showed no
effect of nonspecific NOS inhibition with
NG-nitro-L-arginine
on the magnitude of the change in HR with vagal nerve stimulation (VNS;
1- to 20-Hz stimulation) in the anesthetized rabbit. Recently, we have
reported that NOS inhibition with
NG-monomethyl-L-arginine
slowed the kinetics of the HR response to VNS, without affecting the
magnitude of the HR response in adrenergically stimulated isolated
guinea pig atria and frog heart (26, 28, 29). In contrast, Conlon et
al. (3) reported a large inhibition of the HR response to VNS at all
frequencies of stimulation with NOS inhibition in 
-receptor-blocked
ferrets, although this response was only seen at stimulation
frequencies >8 Hz in anesthetized dogs (5).
The quantitative differences among these studies may result from the effect of endogenous NO on the vagal control of HR being critically dependent on the availability of NOS, the expression of which has been demonstrated to vary among species (36). Therefore, we investigated whether the addition of excessive NO or its intracellular messenger cGMP could significantly modulate the HR response to VNS in vivo and in vitro.
| |
METHODS |
|---|
|
Top
Abstract
Introduction
Methods
Results
Discussion
References
|
|---|
Anesthetized Rabbits
Experiments were carried out under a British Home Office Project Licence (PPL 30/1133).Anesthesia
Nine male New Zealand White rabbits (2.9 ± 0.1 kg) were premedicated with Hypnorm (fentanyl 0.315 mg/ml and fluanisone 10 mg/ml; 0.3 mg/kg im; Janssen). Twenty minutes later, a surgical plane of anesthesia was induced by halothane (2% in 100% oxygen) via an Ayre's T piece with a mask and bag. After surgery, halothane was reduced to 0.5% and anesthesia was maintained with pentobarbital sodium (Sagatal, diluted to 12 mg/ml in saline) administered via a 23-gauge catheter inserted into an ear vein. The electrocardiogram was monitored by using stainless steel electrodes inserted subcutaneously into the left and right arms and left leg. The corneal reflex was tested regularly to ensure adequate anesthesia, and HR was continuously triggered from the arterial blood pressure (ABP) or electrocardiogram record.Surgery
A tracheotomy was performed, and an endotracheal tube (3.5- or 4-mm ID, Portex) was inserted into the trachea (~4 cm) and secured. Sampling of arterial blood, monitoring of ABP, and administration of intravenous drugs were via a cannulated femoral artery and vein (Portex catheters). Animals were artificially ventilated (Oxford, Mark II Ventilator, Penlon) with 100% oxygen, with tidal volume and frequency adjusted to maintain arterial PCO2 and pH within normal physiological limits. Animals were bilaterally vagotomized and cardiac sympathectomized, and the right vagus nerve was dissected free.Intensive Care
Fluid was replaced by an intravenous sterile saline drip (~10-15 ml/h). Urine was removed as required from a catheter inserted into the bladder via the urethra. Heating lamps beneath the operating table were used to maintain body temperature at 38.5 ± 0.3°C, measured by using a rectal temperature probe. Arterial blood samples (0.9 µl/sample) were regularly taken into preheparinized capillary tubes and analyzed for pH, blood gases, and electrolytes (Radiometer ABL505, Copenhagen, Denmark).Measurements
Saline-filled pressure transducers (SensoNor 840) were used to measure systemic ABP. These were calibrated by using a mercury manometer. HR was triggered from the electrocardiogram or the ABP and was digitally displayed. Analog inputs passed to a real-time data-acquisition system (MP 100, Biopac Systems) by using Acqknowledge 3.1 software (Macintosh 950), and signals were also recorded onto a penwriter (MT8P Lectromed). Data were stored on compact disk for later off-line analysis.Stimulation Protocol
The right vagal nerve was stimulated at 5 Hz, 5 V, and 1-ms pulse duration, for 30 s. This stimulation frequency was chosen because it resulted in a repeatable change in HR (~30%) that can reflect HR changes that are seen with physiological alterations of cardiac autonomic balance. The stimulation frequency was submaximal, and ~2 min were left between stimulations. Values of three stimulations that were within 5 beats/min magnitude of one another were accepted, and a mean was calculated. The stimulation protocol was repeated after administration of molsidomine (0.2 mg/kg iv dissolved in 1 ml saline). This dose was chosen because it was within the range used in clinical practice, and after a transient hypotensive effect (~20 min) mean arterial pressure (MAP) returned to the control level. Molsidomine is a NO donor, which is enzymatically metabolized to SIN-1 (linsodomine) in the liver and is then readily converted to the active metabolite SIN-1A. SIN-1 is a sydnonimine that has an unprotected ring structure and in the presence of molecular oxygen undergoes nonenzymatic cleavage to yield NO.Isolated Guinea Pig Atria With Vagus Nerve
Surgery. Twenty-two male guinea pigs (150-200 g) were killed by cervical dislocation followed by exsanguination. The thorax and mediasternum were removed and placed in a Perspex dissecting dish containing oxygenated (95% O2-5% CO2) Tyrode solution at room temperature (for composition see Solutions). The lungs and ventricles were carefully trimmed off. The vagi were separated from the carotid arteries, the left vagus was trimmed away, and the right vagus was isolated and tied. Sutures (Ethicon, 6-0 mersilk) were fixed at the lateral edges of the two atria.
Measurements. The preparations were then transferred to a preheated organ bath containing 60 ml of Tyrode solution. The temperature was monitored by using a Digitron 1408-K temperature gauge and was controlled by recycling water from a temperature-controlled pump (37 ± 0.1°C). Tyrode solution was added from a reservoir that contained a glass coil attached to the temperature controller, so any fluid that was added was already heated. The solution was continuously bubbled with 95% O2-5% CO2.
The suture in the left atrium was attached to a hook, and the suture in the right atrium was tied to a force transducer (HSE F30); thus the preparations were vertically mounted. The transducer was calibrated before the experiment was begun by using a 10-mN weight. The force transducer was connected to an amplifier, and data were collected on a Power Macintosh 8500 computer by using a Biopac MP 100 data-acquisition system and Acqknowledge 3.2 software. The vagus nerve was attached to a silver stimulating electrode with a circular bore. Rate was triggered from contraction and displayed in real time. Data were stored on compact disk for off-line analysis. The preparations were left for ~90 min until a stable HR (±5 beats/min over 20 min) was achieved.Solutions
The Tyrode solution used throughout the experiment contained (in mM) 120 NaCl, 4 KCl, 2 MgCl2, 0.1 NaH2PO4, 11 glucose, 23 NaHCO3, and 2 CaCl2. The solution was bubbled with 95% O2-5%CO2 to give a pH of 7.4. The NO donor sodium nitroprusside (SNP; Sigma Chemical) was added from a stock solution of 0.1 M to give a concentration of 10 or 100 µM (21). The selective hyperpolarization-activated current (If antagonist) 4-(N-ethyl-N-phenylamino)-1,2-dimethyl-6-(methylamino)-pyrimidinium chloride (ZD-7288; Zeneca Pharmaceuticals) was added from a stock solution of 1 mM to give a concentration of 1 µM (2). 8-Bromoguanosine 3',5'-cyclic monophosphate (8-BrcGMP; Sigma Chemical) was added from a stock solution of 0.1 M to give a concentration of 0.5 mM. Carbamylcholine chloride (CCh; Sigma Chemical) was added from a stock solution of 1 mM to give a concentration of 100 nM. Experiments in which SNP or 8-BrcGMP was used were carried out under dark conditions because both of these drugs are light sensitive.Experimental Protocols
Protocol 1. VNS (1, 3, and 5 Hz, 5-10 V, 1-ms pulse duration, for 30 s) was compared before and after addition of SNP, after 20 min of incubation (10 and 100 µM; n = 5, doses added consecutively in the same preparation), and after washout. The order of the stimulations was randomized.
Protocol 2. SNP causes an increase in baseline HR, predominantly due to activation of If (21), which may have affected the vagal nerve response in the presence of the donor. To control for this effect, we carried out experiments with SNP in the presence of 1 µM ZD-7288, which virtually abolishes the baseline shift with 10 µM SNP (21). VNS (5 Hz, 5-10 V, 1-ms pulse duration, for 30 s) was compared before and after addition of the If inhibitor ZD-7288 (1 µM, 40-min incubation; n = 6) and in the continued presence of ZD-7288 after 10 µM SNP. The SNP was then washed off.
Protocol 3. Modulatory effects of NO donors have been reported to occur via the cGMP pathway (for review see Ref. 14). We investigated the role played by this NO-dependent pathway in our response. VNS (5 Hz, 5-10 V, 1-ms pulse duration, for 30 s) was compared before and after addition of the cGMP analog 8-BrcGMP (0.5 mM, 20-min incubation; n = 6). This concentration of 8-BrcGMP gave a shift in baseline similar to that seen with 10 µM SNP.
Protocol 4. To investigate whether the effects of NO donors or 8-BrcGMP on the change in HR with VNS were due to presynaptic or postsynaptic effects of NO, we added the stable analog of the parasympathetic transmitter acetylcholine (CCh; 100 nM) before and after addition of 0.5 mM 8-BrcGMP (n = 5) and after its wash out.
Statistical Analysis
All data are expressed as means ± SE. A one-way analysis of variance with repeated measurements and a post hoc comparison by using Scheffé's test compared the effects of each intervention. P < 0.05 was accepted as statistically significant.| |
RESULTS |
|---|
|
Top
Abstract
Introduction
Methods
Results
Discussion
References
|
|---|
Arterial pH (7.42 ± 0.01), blood gases (arterial
PO2 556.9 ± 24.3 Torr, arterial
PCO2 35.6 ± 0.5 Torr), and
bicarbonate (HCO
3 22.5 ± 0.5 mM)
were well controlled throughout the in vivo experiments.
Effect of Molsidomine on the Change in HR With VNS in Vivo
Molsidomine (0.2 mg/kg iv) significantly enhanced the magnitude of the change in HR with VNS (5 Hz) (Fig. 1). This effect was not reversed within the time course of our experiment. In vivo molsidomine has an elimination half-life of >2 h (19). Molsidomine had no significant effect on baseline HR (control 287.6 ± 12.9 beats/min, molsidomine 293.3 ± 14.4 beats/min), nor did it have any significant effect on MAP after a transient hypotensive effect (control MAP 81.4 ± 6.3 mmHg, molsidomine MAP 84.9 ± 4.1 mmHg).
|
Effect of SNP on the Change in HR With VNS in Vitro
SNP (10 and 100 µM) significantly enhanced the magnitude of the change in HR with VNS at 5 Hz (Fig. 2; n = 6). This was partially reversed on washout of SNP (Fig. 2B). At 3 Hz there was a trend for 10 and 100 µM SNP to enhance the magnitude of the change in HR with VNS (Fig. 2B); however, this was not statistically significant. In both cases there was a significant increase in baseline HR [control 185.0 ± 4.1 beats/min, 10 µM SNP 235.5 ± 15.9 beats/min (P < 0.05), 100 µM SNP 250.0 ± 10.0 beats/min (P < 0.05), washout 209.2 ± 5.4 beats/min].
|
Effect of SNP+ZD-7288 on the Change in HR With VNS in Vitro
To control for the shift in baseline seen with SNP, we repeated experiments in preparations pretreated with the If antagonist ZD-7288 (1 µM), because this is reported to virtually abolish the increase in HR seen with NO donors (21).ZD-7288 (1 µM) significantly decreased the baseline HR (control 226.9 ± 11.2 beats/min, ZD-7288 80.4 ± 9.1 beats/min). There was no
significant difference between baseline HR in ZD-7288 (HR 80.4 ± 0.1 beats/min) and in ZD-7288+SNP (HR 77.4 ± 7.5 beats/min). SNP
(10 µM) still significantly enhanced the magnitude of the HR
response to VNS in the presence of ZD-7288 (Fig.
3). This was reversed with washout of the
SNP.
|
Effect of 8-BrcGMP on the Change in HR With VNS in Vitro
The cGMP analog 8-BrcGMP significantly enhanced the magnitude of the change in HR with 5 Hz VNS (Fig. 4). This was reversed with washout.
|
8-BrcGMP also significantly increased the baseline HR from 214.9 ± 8.6 to 245.2 ± 12.5 beats/min (P < 0.05); this was reversed with washout (HR 211.2 ± 15.1 beats/min).
Effect of 8-BrcGMP on the Change in HR With Bath-Applied CCh in Vitro
8-BrcGMP (0.5 mM) had no significant effect on the magnitude of the change in HR with applied CCh (Fig. 5). The change in HR was 68.2 ± 6.4 beats/min in control, 63.5 ± 12.7 beats/min in 8-BrcGMP, and 64.2 ± 9.7 beats/min after washout (P > 0.05).
|
| |
DISCUSSION |
|---|
|
Top
Abstract
Introduction
Methods
Results
Discussion
References
|
|---|
The role of NO in the cholinergic control of HR is controversial. Its proposed action is via inhibition of adrenergically stimulated ICa L (6), although recent work fails to confirm this and only shows that the transients of ICa L are slowed by NOS inhibition (see Figs. 2 and 5 of Ref. 34). Functionally, inhibition of NOS has been shown to substantially reduce the HR response to VNS (3, 5), have effects only on the transients of the response (28), or have no effect (17). The controversy may arise due to a critical dependence on the availability of NOS within the preparations being studied (36). We therefore tested whether excessive NO or its intracellular messenger cGMP, in addition to the NO-cGMP pathway that is coupled to acetylcholine-muscarinic-receptor activation (8), plays a significant role in the cholinergic control of HR.
Our findings were as follows. 1) Molsidomine enhanced the magnitude of the change in HR with VNS in vivo. 2) Addition of SNP also enhanced the magnitude of the change in HR with VNS in vitro. 3) The increase in the HR response to VNS was not due to the shift in baseline caused by NO donors (21) because it was still present when the change in baseline HR was eliminated with the If inhibitor ZD-7288. 4) The enhancement of the decrease in HR with VNS with NO donors was mimicked by the cGMP analog 8-BrcGMP. 5) The acetylcholine analog CCh, however, did not mimic the HR response to VNS in the presence of 8-BrcGMP, suggesting some presynaptic action for NO.
The enhanced magnitude of the change in HR with VNS with molsidomine was not reversed in vivo due to the long half-life of the drug (19). In contrast, in vitro, the enhanced change in HR with VNS with SNP was reversed with washout, indicating an unlikely nonspecific effect of the donor. Similar results from a study in the anesthetized ferret have recently been published (4).
SNP (10 and 100 µM) significantly increased the baseline HR. This is due to stimulation of If, via a cGMP-dependent pathway (21). It might therefore have been possible that the increase in the magnitude of the HR response to VNS was due to the shift in baseline caused by SNP. We eliminated this shift in baseline HR by using the specific If antagonist ZD-7288 (21) and found the enhanced change in HR with the donor was still present. We did not see a statistically significant increase in baseline HR with molsidomine, which is surprising given that we have seen this before (13). There was, however, high variability in the present data, with six out of the nine rabbits showing an increase in baseline HR, whereas in the other three rabbits HR decreased with molsidomine.
Many of the modulatory effects of NO donors have been reported to occur via the cGMP pathway; NO acts to stimulate soluble guanylate cyclase to produce cGMP (for review see Ref. 14). We found the effect of SNP on the change in HR with VNS was mimicked by application of a stable analog of cGMP, 8-BrcGMP, indicating the cGMP intracellular pathway may be responsible for the effect of the NO donors. Application of 8-BrcGMP did not, however, have any significant effect on the magnitude of the decrease in HR seen with bath-applied CCh, the stable analog of acetylcholine. This would indicate that the effect of NO, via a cGMP-dependent pathway, is through a presynaptic site of action. One could speculate that this could involve an increase in transmitter release, an effect on choline uptake, or acetylation.
Several lines of evidence suggest that cGMP might be acting within the vagal nerve terminal to cause an increased release of acetylcholine. Travagli and Gillis (32) showed in brain slices from the rat that the firing of the dorsal motor nucleus of the vagus was increased by SNP and by L-arginine. This effect was mimicked by dibutyryl cGMP and was inhibited by pretreatment with the guanylate cyclase inhibitor LY-83583. Moreover, in the basal forebrain of conscious rats, Prast and Philippu (24) observed that NO inhibitors decreased and NO donors (SIN-1) enhanced acetylcholine release via a cGMP-dependent mechanism, with the effect of the NO donor being inhibited by the guanylate cyclase inhibitor methylene blue. Electrical stimulation of vagal nerves activates voltage-dependent Ca2+ channels, causing Ca2+ entry and the release of acetylcholine through the Ca2+-dependent phosphorylation of synaptic vesicles. In cardiac tissue, low levels of donors stimulate calcium currents (20) through cGMP-inhibited cAMP phosphodiesterase (PDE), PDE type 3 (20, 22). This isoform of PDE has been identified within neuronal tissue (12), and therefore cGMP inhibition of PDE type 3 could conceivably be involved in an increased release of transmitter with NO donors and cGMP. The results of our study only suggest that NO may enhance transmitter release during VNS. Direct measurement of acetylcholine release is needed to verify this hypothesis, although this may prove difficult given the rapid breakdown of acetylcholine by acetylcholinesterase.
Whether the accentuated HR response to VNS with NO donors/cGMP has any physiological or pathophysiological significance remains to be determined. The effect of NO on the efficacy of cardiac cholinergic stimulation could, however, be potentially important in situations where NO production is enhanced, e.g., septic shock (33), heart failure (11), and exercise training (30).
| |
ACKNOWLEDGEMENTS |
|---|
This work was supported by British Heart Foundation Grant RG 95003. C. E. Sears was supported by a Wellcome Trust Prize Studentship.
| |
FOOTNOTES |
|---|
Some of these results have previously been published in abstract form (27).
The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
Address for reprint requests: C. Sears, Univ. Laboratory of Physiology, Parks Rd., Oxford OX1 3PT, UK (E-mail: claire.sears{at}physiol.ox.ac.uk).
Received 18 June 1998; accepted in final form 18 September 1998.
| |
REFERENCES |
|---|
|
Top
Abstract
Introduction
Methods
Results
Discussion
References
|
|---|
1.
Balligand, J.-L.,
L. Kobzik,
X. Han,
D. M. Kaye,
L. Belhassen,
D. S. O'Hara,
R. A. Kelly,
T. W. Smith,
and
T. Michel.
Nitric oxide-dependent parasympathetic signalling is due to activation of constitutive endothelial (type III) nitric oxide synthase in cardiac myocytes.
J. Biol. Chem.
270:
14582-14586,
1995
2.
BoSmith, R. E.,
I. Briggs,
and
N. C. Sturgess.
Inhibitory actions of ZENECA ZD7288 on whole-cell hyperpolarization activated inward current (If) in guinea-pig dissociated sinoatrial node cells.
Br. J. Pharmacol.
110:
343-349,
1993[Medline].
3.
Conlon, K.,
T. Collins,
and
C. Kidd.
Modulation of vagal actions on heart rate produced by inhibition of nitric oxide synthase in the anaesthetized ferret.
Exp. Physiol.
81:
547-550,
1996[Abstract].
4.
Conlon, K.,
T. Collins,
and
C. Kidd.
Further evidence for nitric oxide modulation of vagal bradycardia in the anaesthetized ferret (Abstract).
J. Physiol. (Lond.)
501P:
79P,
1997.
5.
Elvan, A.,
M. Rubart,
and
D. P. Zipes.
NO modulates autonomic effects on sinus discharge rate and AV nodal conduction in open-chest dogs.
Am. J. Physiol.
272 (Heart Circ. Physiol. 41):
H263-H271,
1997
6.
Han, X.,
L. Kobzik,
J.-L. Balligand,
R. A. Kelly,
and
T. W. Smith.
Nitric oxide synthase (NOS3)-mediated cholinergic modulation of Ca2+ current in adult rabbit atrioventricular nodal cells.
Circ. Res.
78:
998-1008,
1996
7.
Han, X., D. J. Opel, P. L. Huang, C. Fishman,
and R. A. Kelly. Targeted disruption of eNOS impairs
muscarinic cholinergic regulation of
ICa L in murine ventricular
myocytes (Abstract). Circulation 96, Suppl.: 940, 1997.
8.
Han, X.,
Y. Shimoni,
and
W. R. Giles.
An obligatory role for nitric oxide in autonomic control of mammalian heart rate.
J. Physiol. (Lond.)
476:
309-314,
1994
9.
Harada, S.,
S. Tokunaga,
M. Momohara,
H. Masaki,
T. Tagawa,
T. Imaizumi,
and
A. Takeshita.
Inhibition of nitric oxide formation in the nucleus tractus solitarius increases renal sympathetic nerve activity in rabbits.
Circ. Res.
72:
511-516,
1993[Abstract].
10.
Hassall, C. J. S.,
M. J. Saffrey,
A. Belai,
C. H. V. Hoyle,
E. W. Moules,
J. Moss,
H. H. H. W. Schmidt,
F. Murad,
U. Forstermann,
and
G. Burnstock.
Nitric oxide synthase immunoreactivity and NADPH-diaphorase activity in a subpopulation of intrinsic neurones of the guinea-pig heart.
Neurosci. Lett.
143:
65-68,
1992[Medline].
11.
Haywood, G. A.,
P. S. Tsao,
H. E. Von der Leyen,
M. J. Mann,
P. J. Keeling,
P. T. Trindade,
N. P. Lewis,
C. D. Byrne,
P. R. Rickenbacher,
N. H. Bishopric,
J. P. Cooke,
W. J. McKenna,
and
M. B. Fowler.
Expression of inducible nitric oxide synthase in human heart failure.
Circulation
93:
1087-1094,
1996[Medline].
12.
Hidaka, H.,
T. Yamaki,
Y. Ochiai,
T. Asano,
and
H. Yamabe.
Cyclic 3':5'-nucleotide phosphodiesterase determined in various human tissues by DEAE-cellulose chromatography.
Biochim. Biophys. Acta
484:
398-407,
1977[Medline].
13.
Hogan, N.,
B. Casadei,
and
D. J. Paterson.
The nitric oxide donor molsidomine can increase heart rate independent of changes in arterial blood pressure in anaesthetized rabbits (Abstract).
J. Physiol. (Lond.)
505P:
19P,
1997.
14.
Kelly, R. A.,
J.-L. Balligand,
and
T. W. Smith.
Nitric oxide and cardiac function.
Circ. Res.
79:
363-380,
1996
15.
Kelm, M.,
and
J. Schrader.
Control of coronary vascular tone by nitric oxide.
Circ. Res.
66:
1561-1575,
1990[Abstract].
16.
Klimaschewski, L.,
W. Kummer,
B. Mayer,
J. Y. Couraud,
U. Preissler,
B. Philippin,
and
C. Heym.
Nitric oxide synthase in cardiac nerve fibers and neurons of rat and guinea pig heart.
Circ. Res.
71:
1533-1537,
1992[Abstract].
17.
Liu, J.-L.,
H. Murakami,
and
I. H. Zucker.
Effects of NO on baroreflex control of heart rate and renal nerve activity in conscious rabbits.
Am. J. Physiol.
270 (Regulatory Integrative Comp. Physiol. 39):
R1361-R1370,
1996
18.
Mawe, G. M.,
E. K. Talmage,
K. P. Lee,
and
R. L. Parsons.
Expression of choline acetyltransferase immunoreactivity in guinea-pig cardiac ganglia.
Cell Tissue Res.
285:
281-286,
1996[Medline].
19.
Meinertz, T.,
A. Brandstatter,
D. Trenk,
E. Jahnchen,
J. Ostrowski,
and
W. Gartner.
Relationship between pharmacokinetics and pharmacodynamics of molsidomine and its metabolites in humans.
Am. Heart J.
109:
644-649,
1985[Medline].
20.
Mery, P.-F.,
C. Pavoine,
L. Belhassen,
F. Pecker,
and
R. Fischmeister.
Nitric oxide regulates cardiac Ca current.
J. Biol. Chem.
268:
26286-26295,
1993
21.
Musialek, P.,
M. Lei,
H. F. Brown,
D. J. Paterson,
and
B. Casadei.
Nitric oxide can increase heart rate by stimulating the hyperpolarization-activated inward current If.
Circ. Res.
81:
60-68,
1997
22.
Ono, K.,
and
W. Trautwein.
Potentiation by cyclic GMP of -adrenergic effect on Ca2+ current in guinea-pig ventricular cells.
J. Physiol. (Lond.)
443:
387-404,
1991
23.
Patel, K.,
K. Zhang,
I. H. Zucker,
and
T. L. Krukoff.
Decreased gene expression of neuronal nitric oxide synthase in hypothalamus and brainstem of rats in heart failure.
Brain Res.
734:
109-115,
1996[Medline].
24.
Prast, H.,
and
A. Philippu.
Nitric oxide releases acetylcholine in the basal forebrain.
Eur. J. Pharmacol.
216:
139-140,
1992[Medline].
25.
Schwarz, P.,
R. Diem,
N. J. Dun,
and
U. Forstermann.
Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat heart sympathetic nerves.
Circ. Res.
77:
841-848,
1995
26.
Sears, C. E.,
J. K. Choate,
and
D. J. Paterson.
Effect of nifedipine on the rate response to vagal stimulation following inhibition of nitric oxide in the isolated guinea-pig atria.
J. Physiol. (Lond.)
501P:
126P,
1997.
27.
Sears, C. E.,
J. K. Choate,
and
D. J. Paterson.
Nitric oxide donors enhance the heart rate response to vagal nerve stimulation in the anaesthetized rabbit and isolated guinea-pig atria preparation (Abstract).
J. Physiol. (Lond.)
509P:
121P,
1998.
28.
Sears, C. E.,
J. K. Choate,
and
D. J. Paterson.
Inhibition of nitric oxide synthase slows the heart rate recovery from cholinergic activation.
J. Appl. Physiol.
84:
1596-1604,
1998
29.
Sears, C. E.,
and
D. J. Paterson.
Role of nitric oxide in the rate and contraction responses to acetylcholine following adrenergic stimulation in the isolated frog heart (Abstract).
J. Physiol. (Lond.)
495:
167P,
1996.
30.
Sessa, W. C.,
K. Pritchard,
N. Seyedi,
J. Wang,
and
T. H. Hintze.
Chronic exercise in dogs increases coronary vascular nitric oxide production and endothelial cell nitric oxide synthase gene expression.
Circ. Res.
74:
349-353,
1994[Abstract].
31.
Tanaka, K.,
and
T. Chiba.
Nitric oxide synthase containing nerves in the atrioventricular node of the guinea-pig heart.
J. Auton. Nerv. Syst.
51:
245-253l,
1995[Medline].
32.
Travagli, R. A.,
and
R. A. Gillis.
Nitric oxide-mediated excitatory effect on neurons of dorsal motor nucleus of vagus.
Am. J. Physiol.
266 (Gastrointest. Liver Physiol. 29):
G154-G160,
1994
33.
Ungureanu-Longrois, D.,
J.-L. Balligand,
R. A. Kelly,
and
T. W. Smith.
Myocardial contractile dysfunction in the systemic inflammatory response syndrome: role of a cytokine-inducible nitric oxide synthase in cardiac myocytes.
J. Mol. Cell. Cardiol.
27:
155-167,
1995[Medline].
34.
Vandecasteele, G.,
T. Eschenhagen,
and
R. Fischmeister.
Role of the NO-cGMP pathway in the muscarinic regulation of the L-type Ca2+ current in human atrial myocytes.
J. Physiol. (Lond.)
506:
653-663,
1998
35.
Yoshida, K.,
and
N. Toda.
NADPH diaphorase-positive neurons in the intracardiac plexus of human, monkey and canine right atria.
Brain Res.
724:
256-259,
1996[Medline].
36.
Zanzinger, J.,
and
H. Seller.
Species differences in the distribution of nitric oxide synthase in brain stem regions that regulate sympathetic activity.
Brain Res.
764:
265-268,
1997[Medline].
This article has been cited by other articles:
|
|
 |
|
  D. A. Heaton, D. Li, S. C. Almond, T. A. Dawson, L. Wang, K. M. Channon, and D. J. Paterson Gene Transfer of Neuronal Nitric Oxide Synthase into Intracardiac Ganglia Reverses Vagal Impairment in Hypertensive Rats Hypertension, February 1, 2007; 49(2): 380 - 388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J. DANSON and D. J. PATERSON Cardiac Neurobiology of Nitric Oxide Synthases Ann. N.Y. Acad. Sci., June 1, 2005; 1047(1): 183 - 196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Farias III, K. Jackson, M. Johnson, and J. L. Caffrey Cardiac enkephalins attenuate vagal bradycardia: interactions with NOS-1-cGMP systems in canine sinoatrial node Am J Physiol Heart Circ Physiol, November 1, 2003; 285(5): H2001 - H2012. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Choate and R. Feldman Neuronal control of heart rate in isolated mouse atria Am J Physiol Heart Circ Physiol, August 7, 2003; 285(3): H1340 - H1346. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R.M. Mohan, D.A. Heaton, E.J.F. Danson, S.P.R. Krishnan, S. Cai, K.M. Channon, and D.J. Paterson Neuronal Nitric Oxide Synthase Gene Transfer Promotes Cardiac Vagal Gain of Function Circ. Res., December 13, 2002; 91(12): 1089 - 1091. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Herring, E. J. F. Danson, and D. J. Paterson Cholinergic Control of Heart Rate by Nitric Oxide is Site Specific Physiology, October 1, 2002; 17(5): 202 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Takimoto, T. Aoyama, K. Tanaka, R. Keyamura, Y. Yui, and S. Sasayama Augmented Expression of Neuronal Nitric Oxide Synthase in the Atria Parasympathetically Decreases Heart Rate During Acute Myocardial Infarction in Rats Circulation, January 29, 2002; 105(4): 490 - 496. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Chowdhary, S. L. Nuttall, J. H. Coote, and J. N. Townend L-Arginine Augments Cardiac Vagal Control in Healthy Human Subjects Hypertension, January 1, 2002; 39(1): 51 - 56. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. K. Choate, E. J. F. Danson, J. F. Morris, and D. J. Paterson Peripheral vagal control of heart rate is impaired in neuronal NOS knockout mice Am J Physiol Heart Circ Physiol, December 1, 2001; 281(6): H2310 - H2317. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Herring, J. A. B. Zaman, and D. J. Paterson Natriuretic peptides like NO facilitate cardiac vagal neurotransmission and bradycardia via a cGMP pathway Am J Physiol Heart Circ Physiol, December 1, 2001; 281(6): H2318 - H2327. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Herring, L. Rigg, D. A Terrar, and D. J Paterson NO-cGMP pathway increases the hyperpolarisation-activated current, If, and heart rate during adrenergic stimulation Cardiovasc Res, December 1, 2001; 52(3): 446 - 453. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Musialek and B. Casadei Nitrovasodilators and heart rate: more than the arterial baroreflex Cardiovasc Res, August 1, 2000; 47(2): 404 - 405. [Full Text] [PDF]
|
|
|
|
|
|
J.-L. Balligand Regulation of cardiac {beta}-adrenergic response by nitric oxide Cardiovasc Res, August 15, 1999; 43(3): 607 - 620. [Full Text] [PDF]
|
|
|
|
|
|
N. Hogan, A. Kardos, D. J. Paterson, and B. Casadei Effect of exogenous nitric oxide on baroreflex function in humans Am J Physiol Heart Circ Physiol, July 1, 1999; 277(1): H221 - H227. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
